Evidence map›Paper›PMID 39545604›Full record

ReviewFuture oncology (London, England)2025

Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors.

Arafat Tfayli, Hady Ghanem, Fadi Nasr, Hampig Raphael Kourie, Georges El Hachem, Jamil Debs, Sarah Masri, Hazem I Assi, Rosario García Campelo, Joseph Kattan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arafat TfayliHematology-Oncology Division, American University of Beirut Medical Center, Beirut, 1107 2020, Lebanon.ORCID 0000-0002-0633-2538
Hady GhanemHematology-Oncology Division, Lebanese American University Medical Center - Rizk Hospital, Beirut, 11-3288, Lebanon.ORCID 0000-0002-3575-2187
Fadi NasrDepartment of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, 166830, Lebanon.ORCID 0000-0002-0616-903X
Hampig Raphael KourieDepartment of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, 166830, Lebanon.ORCID 0000-0002-2502-5402
Georges El HachemDepartment of Hematology & Medical Oncology, Saint George Hospital University Medical Center, Beirut, Lebanon.ORCID 0000-0003-3919-7085
Jamil DebsPfizer Inc, 166-378, Levant.
Sarah MasriPfizer Inc, 166-378, Levant.
Hazem I AssiDepartment of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, 1107 2020, Lebanon.ORCID 0000-0002-8483-0938
Rosario García CampeloDepartment of Medical Oncology, Hospital Universitario A Coruña, 15006, A Coruña, Spain.ORCID 0000-0003-2113-1504
Joseph KattanDepartment of Hematology-Oncology, Hôtel-Dieu de France University Hospital, Faculty of Medicine, Saint-Joseph University of Beirut, Beirut, 166830, Lebanon.ORCID 0000-0003-4576-6248

Funding

Pfizer N/A
6 · The paper itself

Abstract

Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with

Indexed as

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsHumansLebanonMolecular Targeted TherapyNeoplasm StagingTyrosine Kinase InhibitorsALK protein, humanAnaplastic Lymphoma KinaseProtein Kinase InhibitorsTyrosine Kinase InhibitorsALK-rearrangementALK-tyrosine kinase inhibitorexpert opinionlung cancernon-small-cell lung cancer

Identifiers

PMID39545604
PMCPMC11759622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.